glp 1 month results Our GLP-1 Weight Loss Journey My 1 month results while

Satiety regulation (reduces appetite, aiding in weight loss)

GLP-1 Market Size, Share & Trends Analysis Report By Type of GLP-1 Agonist Drugs (Long-acting GLP-1 Agonist, Short-acting GLP-1 Agonist), By Type of Agonist (Single Agonist, Dual Agonist, Tri-agonist), By Molecule Type (Biologic Peptide GLP-1 Agonists, Small-Molecule Non-Peptide GLP-1 Agonists), By Active Compound (Semaglutide, Tirzepatide, Dulaglutide, Liraglutide, Lixisenatide, Exenatide, Orforglipron, Retatrutide, Survodutide, Other Active Compounds), By Route of Administration (Oral, Parenteral), By Dosing Frequency (Daily, Weekly, Monthly or Extended-Interval), By Delivery System, By Target Indication, By Payer, By Region and By Segments Forecasts, 2026 to 2035

The study highlights that patient-reported data from social media may capture experiences that are not consistently documented in formal adverse event reporting systems

Xie C, Alkhouri N, Elfeki MA

Novel formulations and delivery systems The most recent stage of GLP-1RA development has been focused on novel delivery mechanisms and formulations to improve patient comfort and compliance

Besides common gastrointestinal issues, Semaglutide has also been linked to temporary worsening of diabetic retinopathy with rapid blood sugar improvements, hypoglycemia, gallbladder problems, thyroid and pancreatic safety, heart health, kidney injury, diabetic retinopathy, and allergic reactions